Vancouver, Wash.-based CytoDyn raised $14.5 million to fund current operating expenses and continue development of its primary drug candidate, PRO 140, believed to be one of the leading monoclonal antibodies for treatment of HIV.
http://www.bizjournals.com/portland/blog/health-care-inc/2013/10/cytodyn-raises-145m-to-fuel-hiv-drug.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_portland+%28Portland+Business+Journal%29
http://www.bizjournals.com/portland/blog/health-care-inc/2013/10/cytodyn-raises-145m-to-fuel-hiv-drug.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_portland+%28Portland+Business+Journal%29
No comments:
Post a Comment